Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

Background: To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevaci...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2009

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/24173

Acceso en línea:

https://doi.org/10.1007/s00417-008-1034-x
https://repository.urosario.edu.co/handle/10336/24173

Palabra clave:

Bevacizumab
Adult
Article
Cerebrovascular accident
Clinical trial
Comparative study
Controlled clinical trial
Controlled study
Cornea thickness
Diabetic macular edema
Dose response
Drug dose comparison
Drug efficacy
Drug safety
Drug stability
Female
Fluorescence angiography
Follow up
Heart infarction
Human
Hypertension
Intraocular pressure
Major clinical study
Male
Multicenter study
Off label drug use
Ophthalmoscopy
Optical coherence tomography
Peripheral vascular disease
Priority journal
Retina detachment
Side effect
Thromboembolism
Transient ischemic attack
Visual acuity
Angiogenesis inhibitors
Cooperative behavior
Diabetic retinopathy
Female
Fluorescein angiography
Follow-up studies
Humans
Injections
Macular edema
Male
Middle aged
Retina
Retreatment
Retrospective studies
Treatment outcome
Vascular endothelial growth factor a
Visual acuity
Vitreous body
Avastin
Bevacizumab
Diffuse diabetic macular edema
Intravitreal injections
Oct
Primary treatment
optical coherence
monoclonal
Antibodies
Tomography

Rights

License

Abierto (Texto Completo)